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provided it is propeObjective: The incidence of human papillomavirus (HPV)-related oral malignancies
is increasing among HIV-infected populations, and the prevalence of oral warts has
reportedly increased among HIV patients receiving antiretroviral therapy (ART). We
explored whether ART initiation among treatment-naive HIV-positive adults is followed
by a change in oral HPV infection or the occurrence of oral warts.
Design: Prospective, observational study.
Methods: HIV-1 infected, ART-naive adults initiating ART in a clinical trial were
enrolled. End points included detection of HPV DNA in throat-washes, changes in
CD4þ T-cell count and HIV RNA, and oral wart diagnosis.
Results: Among 388 participants, 18% had at least one HPV genotype present before
initiating ART, and 24% had at least one genotype present after 12–24 weeks of ART.
Among those with undetectable oral HPV DNA before ART, median change in CD4þ
count from study entry to 4 weeks after ART initiation was larger for those with
detectable HPV DNA during follow-up than those without (P¼ 0.003). Both prevalence
and incidence of oral warts were low (3% of participants having oral warts at study
entry; 2.5% acquiring oral warts during 48 weeks of follow-up).
Conclusion: These results suggest: effective immune control of HPV in the oral cavity
of HIV-infected patients is not reconstituted by 24 weeks of ART; whereas ART initiation
was not followed by an increase in oral warts, we observed an increase in oral HPV
DNA detection after 12–24 weeks. The prevalence of HPV-associated oral malignan-
cies may continue to increase in the modern ART era.
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Oncogenic human papillomavirus (HPV) genotypes
associated with the pathogenesis of oropharyngeal cancer
and nononcogenic genotypes associated with develop-
ment of oral warts are both found in the oral cavity [1].
Studies report up to 56% of HIV-infected adults have
detectable oral HPV DNA, a proportion substantially
higher than reported in non-HIV-infected populations
[2–5], and that oral HPV DNA and oncogenic HPV
genotypes are more prevalent and have a higher incidence
among HIV-positive than HIV-negative MSM [6].
There are also recent reports of an increasing incidence
of HPV-related oropharyngeal malignancies among the
US population living with HIV infection, despite the
widespread availability of effective combination antire-
troviral therapy (ART) for almost two decades [7–9].
However, the impact of ART and associated immune
reconstitution on HPV replication in the oropharynx has
not previously been prospectively examined.
Retrospective studies have reported that the use and
increased duration of ART were associated with the
detection of HPV DNA in oral secretions [4], and that
oral HPV DNA has been detected more frequently in
HIV-infected patients who were virologically suppressed
than those not suppressed on ART [5]. Studies have also
suggested that the prevalence of HPV-associated oral
warts is increased in HIV-infected patients after initiating
ART [10,11]. These findings are counterintuitive since
the degree of immune reconstitution resulting from
virologically effective combination ART controls other
AIDS-associated opportunistic infections caused by DNA
viruses, such as herpes simplex virus (HSV), cytomega-
lovirus (CMV), Epstein–Barr virus, and JC virus [12].
These retrospective findings led us to hypothesize that
HPV in the oropharynx would persist in HIV-infected
patients after ART initiation. If true, the potential for
development of HPV-related oral warts and carcinomas
might further increase among HIV-infected individuals
on ART, who already have an increased risk of solid
tumors despite long-term suppression of HIV replication
[10]. In particular, the risk of oropharyngeal, anal, and
cervical cancer (all of which can be HPV-associated) are
3–60-fold higher among HIV-infected patients in the
modern ART era than in the contemporaneous general
population, and the incidence of oropharyngeal and anal
cancer have significantly increased in the HIV-infected
population compared with the premodern ARTera when
survival among the HIV-infected was much shorter [10].
Therefore, AIDS Clinical Trial Group (ACTG) protocol
A5272 sought to explore the changes that occur in
oral HPV DNA detection among treatment-naive
HIV-positive adults over the first 24 weeks after initiating
ART, as well as the prevalence of oral warts prior to and
48 weeks after ART initiation. We further explored
oral HPV DNA detection in relation to immunereconstitution, measured by change in the absolute
CD4þ cell count change and control of HIV replication.
Our analyses accounted for oral sex behavior prior and
during the study period.Methods
Study design and population
A5272 was a prospective, observational study of HIV-1
infected ART-naı̈ve adults (18 years old) initiating ART
in a controlled clinical trial [13,14] (Table 1). Participants
were seen at five visits over 48 weeks. Visits were
scheduled at two time points within 1 week prior to
ART initiation (study preentry and entry), during a 12–
18-week time-interval following ART initiation, and at
24 and 48 weeks after ART initiation. All participants
provided written informed consent. The protocol was
approved by the institutional review boards of all
participating sites.
Variables and measures
Throat-wash specimens were collected at each of the first
four time points (study preentry, study entry, any time
between weeks 12 and 18, and week 24). An oral soft
tissue examination was performed at entry and weeks
12–18, 24, and 48. CD4þT-cell count and plasma HIV-1
RNA (using an assay with a lower level of detectability
of 40 copies/ml) were measured at entry and weeks 4,
12–18, 24, and 48 (or at discontinuation if a participant
exited the study prematurely). Detailed medical history
was obtained and a sexual behavior questionnaire
administered at study entry. The questionnaire was
repeated 24 weeks after ART initiation.
Oral human papillomavirus detection and typing
Real-time PCR reactions were performed using Roche
Lightcycler TaqMan master mix. Each reaction consisted
of 1X Roche Lightcycler TaqMan master mix (Roche
Diagnostics, Indianapolis, Indiana, USA), HPV-specific
primer pairs and fluorescently-tagged probes for types 6,
11, 16, and 18 in a total reaction volume of 10 ml as
previously described [15]. Real-time PCR reactions that
target the E1 region of HPV were performed using
Roche Lightcycler Sybr Green master mix (Roche
Diagnostics), and sequencing of PCR products was
performed as previously described [15].
Statistical analyses
Standard summary statistics were used to describe sample
characteristics [proportions for categorical variables and
median with first and third (Q1 and Q3) quartiles for
continuous variables]. We computed prevalence of oral
warts at study entry and incidence over the 48 weeks
following ART initiation. Baseline prevalence of oral
HPV infection was defined as having HPV DNA of any
type detectable in at least one of the two throat wash
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Table 1. Characteristics of participants (N U 388)a in AIDS Clinical
Trial Group 5272 enrolled at 39 Clinical Research Sites from 2
January 2010 to 4 June 2012 prior to antiretroviral therapy initiation






Black, non-Hispanic 152 (39)
White, non-Hispanic 139 (36)
Hispanic 87 (22)
Other 10 (3)
Intravenous injection drug use
Never 365 (94)
Previously 23 (6)
Reported number of oral sex partners
during 6 months prior to ART initiation
0 77 (26)
1 94 (31)
2 or more 128 (43)
Reported number of oral sex partners
between baseline visit and 24-week
visit (or following ART initiation)
0 145 (41)
1 118 (33)
2 or more 91 (26)
Median (Q1, Q3)
Age at study entry (years) 38 (29–47)
CD4þ T-cell count (cells/ml)
At study entry (N¼385) 328 (174–455)
4 weeks after initiating ART (N¼359) 402 (249–559)
12–18 weeks after initiating ART (N¼388) 447 (290–592)
24 weeks after initiating ART (N¼387) 483 (311–647)
Plasma HIV-1 RNA (log10 copies/ml)
At study entry (N¼387) 4.68 (4.20–5.22)
4 weeks on ART (N¼379) 2.40 (1.81–2.89)
12–18 weeks on ART (N¼388) <1.60 (1.60–1.77)
24 weeks on ART (N¼387) <1.60 (1.60–1.60)
ACTG, AIDS Clinical Trial Group; ART, antiretroviral therapy; HPV,
human papillomavirus.
aParticipants who had evaluable throat wash HPV DNA results from
both time points before initiating ART and again after 12–18 and 24
weeks of ART.
bACTG Protocol A5257: phase III comparative study of three non-
nucleoside reverse-transcriptase inhibitor-sparing antiretroviral regi-
mens for treatment-naive HIV-1-infected volunteers (N¼268) [14],
ACTG Protocol A5280: Prospective, randomized, double-blind phase
II trial of vitamin D and calcium in HIV-1-infected individuals
initiating efavirenz/emtricitabine/tenofovir (N¼87), ACTG Protocol
A5303: phase IIb, double-blind, placebo-controlled, randomized trial
of a novel, maraviroc-containing antiretroviral regimen in treatment-
naı̈ve HIV-1 infected participants (N¼25) and two industry-spon-
sored ART treatment trials (N¼120), ERTO: Antiretroviral activity and
tolerability of etravirine in treatment-naı̈ve adults with HIV-1 infec-
tion and Gilead GS-US-264–0110 Study: Evaluation of the safety and
efficacy of emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil
fumarate (TDF) compared with tefavirenz/FTC/TDF in ART-naive
HIV-1 infected adults [13,14].specimens collected before ART initiation. Incidence
was the proportion of participants who had oral HPV
detected at one or both follow-up visits (weeks 12–18
and/or week 24 after initiating ART) among those
undetectable at study preentry and entry. Our analysis
included only those participants who had available
specimens for all four time points. To account for oral
sex behavior, which may be associated with acquisition oforal HPV during the study period, we compared number
of oral sex partners reported during the past 6 months at
study entry and 24 weeks following ART initiation using:
a nonparametric approach (Wilcoxon signed-rank test);
and a contingency table method after categorizing
participants as reporting 0, 1, or more than 1 partners
(Fisher’s exact test).
We estimated prevalence of oral type-specific HPV
infection at baseline and 12–24 weeks follow-up. Finally,
we determined the proportion of ‘oral HPV persisters’
(individuals who had the same HPV genotype detected at
preentry or entry and again at weeks 12–18 or 24); ‘oral
HPV clearers’ (individuals who had a specific genotype
detected at preentry or entry but not subsequently at
weeks 12–18 or 24; and ‘oral HPVacquirers’ (individuals
with a specific genotype detected at weeks 12–18 or
24 that was not detected at preentry or entry). We also
assessed proportions of persisters, clearers, and acquirers
for oncogenic vs. nononcogenic HPV genotypes and
by gender.
We computed median change in absolute CD4þ T-cell
count and HIV viral load between study entry and three
follow-up time points (weeks 4, 12–18, and 24) with a
Mann–Whitney rank-sum test to compare distribution of
the change in absolute CD4þT-cell count and HIV RNA
load at these three time points among those who did not
have oral HPV DNA detected over time, and among
those who did. We also compared age, and number of
past-6-month oral sex partners reported at the 24-week
visit, between these two groups using a Mann–Whitney
rank-sum test.Results
Sample characteristics
A total of 39 sites (see appendix) recruited 500
participants from 2 January 2010 to 4 June 2012. Among
the 500 enrolled in this protocol, 388 had evaluable
throat-wash HPV DNA results from both time points
before initiating ARTand again after 12–18 and 24 weeks
of ART and are included in this analysis. We found no
difference with respect to race, history of injection drug
use, entry CD4þT-cell count or HIV RNA load between
the 388 included in the analysis and the 112 excluded
because of missing HPV DNA data points.
Among the 388 participants included in this analysis, the
majority was men (81%) and had never used illicit
intravenous drugs (94%; Table 1). One-third were White
non-Hispanic, 39% were Black non-Hispanic, and the
median age at enrollment was 38 years. The median
CD4þ T-cell count at study entry was 328 cells/ml, and
median plasma HIV RNA was 4.68 log10 copies/ml.
After 24 weeks of ART, the median CD4þ T-cell count
1576 AIDS 2016, Vol 30 No 10was 483 cells/ml, the plasma HIV RNA was less than
1.60 log10 copies/ml; 81% of participants had an
undetectable viral load (<40 copies/ml), and 100% had
less than 500 copies/ml.
Detection of human papillomavirus DNA
Seventy study participants [18%, 95% confidence interval
(CI): 14%, 22%] had HPV DNA detected in their throat
wash prior to initiating ART, and 93 study participants
(24%, 95% CI: 20%, 29%) had HPV DNA detected after
12–18 or 24 weeks of ART (Table 2). Among those who
did not have HPV DNA present in their throat wash
before initiating ART, 15% (95% CI: 11%, 20%) had an
oral specimen in which HPV DNA was detected after
12–18 or 24 weeks of ART. In addition, after 12–18 or
24 weeks of ART, 20% (95% CI: 16%, 24%) of the entire
cohort had a new HPV genotype detected in throat wash
that was not identified in the specimens obtained before
initiating ART (Fig. 1). Also, among the 68 study
participants who had typeable HPV DNA present before
initiating ART, only 46 (75%, 95% CI: 63%, 86%) cleared
one or more of these genotypes during follow-up,
whereas 15 (28%, 95% CI: 17%, 41%) persisted in having
at least one of the genotypes present before ART detected
during follow-up.
The proportion of individuals with detectable HPV DNA
at baseline or follow-up was not different between men
and women (Table 2). Among those who had evidence of
HPV oral infection before initiation of ART, 63% had
discordant HPV DNA test results between the preentry
and entry visits (one was positive and one negative).
Similar analysis after ART initiation revealed 69% had
discordant test results at 12–18 weeks and 24 weeks.
The mean difference in the number of oral sex partners
reported in the past 6 months assessed at the 24-week visit
vs. the baseline visit was 1.59 (P< 0.0001, Wilcoxon
signed-rank test), Furthermore, contingency table
analysis showed 44% reported more than one oral sex
partners in the past 6 months at study entry vs. 29%
when assessed at 24-week follow-up (P< 0.0001;
note: proportions are slightly different from those inTable 2. Prevalence of oral human papillomavirus DNA among participants




Any oral HPV genotype detected at baseline 70 (18
Any oral oncogenic HPV genotype detected at baseline 18 (5)
Any oral HPV genotype detected during follow-up 93 (24
Any oral oncogenic HPV genotype detected during follow-up 21 (5)
CI, confidence interval; HPV, human papillomavirus.
aThe mean difference between reported number of oral sex partners in the p
1.59. A Wilcoxon signed-rank test revealed that this difference was s
significantly fewer oral sex partners during the 6 months following ART in
b95% confidence interval for the percentage.
cx2 test comparing HPV DNA prevalence between men and women.Table 1 because of some missing observations in the
cross-tabulation).
Detection of genotype-specific oral human
papillomavirus infection
The most common genotypes of HPV detected in throat
wash specimens at baseline was HPV 44 (18%), followed
by HPV 32 (16%), which is commonly found in focal
epithelial hyperplasia, followed by HPV 16 (14%), an
oncogenic genotype (Fig. 2). Six of the 20 genotypes
detected were high-risk oncogenic genotypes (16, 35, 39,
56, 73, and 82). The prevalence of any oncogenic
genotype was 5% (95% CI: 3%, 7%) before and 5% (95%
CI: 3%, 8%) after 12–24 weeks of ART (Table 2). Among
participants with an oral oncogenic HPV genotype
detected at baseline, 58% cleared it after 12–24 weeks
of ART, whereas 42% either persisted with the same type,
or acquired another oncogenic type while clearing
the genotype present at baseline. Four percentage of
participants acquired a new oncogenic genotype that
was not present at baseline.
New oral human papillomavirus DNA infection
by change in CD4R T-cell count and HIV RNA
load over time
Among participants who had undetectable oral HPV
DNA before ART, the median change in CD4þ T-cell
count from study entry to 4 weeks after ART initiation
was significantly larger in the subset who had detectable
HPV DNA during follow-up than in the subset who did
not (P¼ 0.003; Table 3). A difference was also observed
with larger CD4þ T-cell increases among the acquirers at
12–18 weeks after ART initiation (P¼ 0.04), but this was
not statistically significant at the 0.05 level at 24 weeks
after ART initiation (P¼ 0.08). With respect to change in
plasma HIV RNA from baseline to 4 weeks, or 12–18, or
24 weeks after ART initiation, no difference was observed
when comparing those who had detectable oral HPV
DNA after ART initiation with those who did not.
We also compared age, and number of past 6-month oral
sex partners reported at the 24-week visit among




n (%) [95% CI]b
Women (N¼75)
n (%) [95% CI]b P valuec
) [14, 22] 62 (20) [16, 25] 8 (11) [5, 20] 0.06
[3, 7] 14 (4) [2, 7] 4 (5) [1, 13] 0.75
) [20, 29] 71 (23) [18, 28] 22 (29) [19, 41] 0.23
[3, 8] 14 (4) [2, 7] 7 (9) [4, 18] 0.10
ast 6 months assessed at the 24-week visit and at the baseline visit was
tatistically significant (P<0.0001), indicating that participants had
itiation than in the 6 months prior to ART initiation.




































HPV genotype at baseline
Fig. 2. (a) Frequency of each HPV genotype at baseline (preentry













Fig. 1. Oral HPV genotype change over time. (a) ‘Persisters’
are defined as individuals who had at least one genotype of
HPV detected in throat washings at either the screening/
preentry or the entry visit and again had that same type
detected at either weeks 12–18 or 24. Note: six participants
persisted with one HPV genotype and acquired a new one. (b)
‘Clearers’ are defined as individuals who had at least one
genotype of HPV detected in throat washings at either the
screening/preentry or the entry visit but did not have that
genotype detected at week 12–18 or 24. (c) ‘Acquirers’ are
defined as individuals who were had at least one genotype of
HPV detected in throat washings at either week 12–18 or 24
for which that genotype was not detected at either the screen-
ing/preentry or the entry visits. Note: 16 participants had at
least one HPV genotype detected at one of the baseline visits
but not at either of the follow-up visits and had a new
genotype, not detected at baseline that was detected in at
least one of the follow-up visits. HPV, human papillomavirus.DNA over 24 weeks after ART initiation, which revealed
no statistically significant difference between the two
groups for either variable (Mann–Whitney rank-sum test
P¼ 0.202 and P¼ 0.342, respectively).
Detection of oral warts
At entry, 3% (95% CI: 2%, 5%) of participants were found
to have oral warts. After 48 weeks of follow-up, 2.5%
(95% CI: 1%, 4%) of study participants who did not have
oral warts at entry and had developed oral warts during
follow-up.Discussion
In this prospective study of 388 previously untreated
HIV-infected patients, we observed no reduction in
overall oral HPV DNA prevalence or in the prevalence of
oncogenic oral HPV genotypes after 12–24 weeks of
ART despite a high rate of HIV virologic suppression and
robust immune reconstitution as indicated by absolute
CD4þT-cell count increase. Among those with oral HPV
DNA that could be genotyped before initiating ART,
28% persisted in having at least one of the genotypes still
detectable during follow-up; and among participants with
an oral oncogenic HPV genotype detected at baseline,
42% either persisted with the same type or acquired
another oncogenic type during follow-up. This lack of
reduction of overall HPV DNA prevalence was observed
despite a significantly lower number of oral sex partners
reported by participants during the 6 months following
ART initiation than the 6 months prior to initiation.
We also observed that both oral wart prevalence at
baseline and incidence during 48 weeks of follow-up
were low. Most remarkably, among those who had




























HPV genotype at follow-up
and entry); (b) frequency of each HPV genotype at follow-up
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Table 3. Comparison, among those who did not have detectable oral human papillomavirus DNA at baseline, of absolute CD4R T cell and HIV















At week 4 Median [Q1; Q3] 79 [20–132] 125 [54–213] 0.003
N¼267 N¼48
At weeks 12–18 Median [Q1; Q3] 116 [53–195] 163 [77–274] 0.04
N¼267 N¼48
At week 24 Median [Q1; Q3] 144 [71–245] 190 [94–292] 0.08
Log10 HIV RNA load change
after ART initiation
N¼264 N¼48
At week 4 Median [Q1; Q3] 2 [2–3] 2 [2–3] 0.34
N¼270 N¼48
At weeks 12–18 Median [Q1; Q3] 2 [2–2] 2 [2–2] 0.73
N¼270 N¼48
At week 24 Median [Q1; Q3] 2 [2–2] 2 [2–2] 0 79
ART, antiretroviral therapy; HPV, human papillomavirus.
aA Mann–Whitney rank-sum test comparing age and number of past 6-month oral sex partners reported at the 24-week visit among participants
with and without detectable oral HPV DNA over 24 weeks after ART initiation revealed no statistically significant difference between the two
groups for either variable (P¼0.202 and P¼0.342, respectively).
bMann–Whitney rank-sum test.increase in CD4þ T-cell count from study entry to
4 weeks after ART initiation was paradoxically larger in
the subset of study participants with new detectable HPV
DNA during follow-up than in the subset that continued
to have undetectable HPV DNA in their throat
wash specimens.
The prevalence of oral HPV infection and incidence of
new oral infection have been previously examined in
HIV-infected and uninfected cohorts of men, though not
in the context of ART initiation. Kreimer et al. tested oral
specimens for HPV DNA at 6-month intervals in 1626
HIV-uninfected men enrolled in Brazil, Mexico, and the
United States; MSM made up only 11% of this cohort
[16]. The point prevalence of HPV DNA in baseline
throat washings was 4%, and the incidence of new HPV
infection during 12 months of follow-up among those
who were HPV DNA negative at baseline was 4.4% (95%
CI 3.5%, 5.6%). The prevalence of oncogenic HPV
infection was 2.4% and the incidence of oncogenic HPV
infection was 1.7% during 12 months of follow-up. King
et al. reported a point prevalence of 13.7% for any oral
HPV genotype and 5.9% for oral oncogenic HPV
genotypes in a cohort of 151 HIV-uninfected MSM [17].
Mooij et al. [6] reported on a cohort of 453 HIV-
uninfected and 314 HIV-infected MSM enrolled in
Amsterdam that had considerably higher prevalence rates
– 27.6% for any oral HPV DNA in HIV-uninfected
MSM and 56.7% in HIV-infected MSM; 8.8 and 24.8%
for oncogenic HPV infection, respectively. Among those
evaluable at 6-month follow-up, 4.1% of HIV-uninfectedMSM and 14.1% of HIV-infected MSM had acquired a
new oncogenic oral HPV infection [6]. Among the 388
HIV-infected men enrolled in our cohort, oral HPV
prevalence values were between those of these previous
studies, perhaps reflecting the increased risk that MSMs
have for oral HPVacquisition independent of HIV status
[16,17].
The intriguing finding that evidence of HPV DNA
was detected more frequently among those who had the
largest increases in circulating absolute CD4þ T-cell
counts does suggest that activation of latent HPV
infection might be an epiphenomenon of immune
reconstitution in HIV patients. Replication of the
chronic human herpesvirus infections, CMV, and HSV
has been prospectively examined among HIV-infected
patients initiating ART. Several studies have reported a
significant, progressive decline in CMV viremia in the
absence of specific anti-CMV therapy after HIV-infected
cohorts have initiated ART [18,19]. There is one report
that the frequency of vaginal HSV-2 DNA detection
among Ugandan HIV-infected women transiently
increased immediately after ART initiation, remained
elevated in the absence of concomitant acyclovir therapy
for 12 weeks, and then returned to pre-ART levels [20].
However, unlike oral HPV DNA detection in HIV-
infected patients, the frequency of HSV-2 vaginal
detection before and after 6 months of ART in this
study was similar to that previously reported in sexually
active, HIV-seronegative African women [21]. Never-
theless, this study did find a trend toward those with
Oral human papillomavirus infection Shiboski et al. 1579greater increases in CD4þ T-cell counts after initiating
ART having more frequent HSV-2 shedding, as we
observed to be statistically significant for oral HPV
shedding in our study. This same group more recently
reported a transient increase in proportion of Ugandan
HIV-infected women from whom CMV DNA could be
detected in the vagina between 8 and 16 weeks after ART
initiation – perhaps another possible mucosal epiphe-
nomenon of immune reconstitution [22].
Given the increased incidence of HPV-associated
oropharyngeal squamous cell carcinoma (SCC) that has
been reported in the last 2 decades in the HIV-infected
population [9], our findings are concerning. One-third of
oral HPV detected in our study were oncogenic
genotypes. The greatest risk factor for development of
malignancy is HPV persistence. Although this association
is best established for cervical cancer where cancer arises
from a small, well defined anatomic area (the transform-
ation zone), it may apply to oropharyngeal SCC as well.
Although previously published studies have suggested that
HPV may persist in oral sites among HIV patients
receiving combination ART, this study is the first to
prospectively examine the association of initiating ART
(and the degree of therapy-related immune reconstitution
as measured by absolute CD4þ T-cell count increase)
with clearance of oral HPV DNA. Not only did we find
no evidence of a reduction in oral HPV resulting from
ART, we observed that study participants with the largest
increases in circulating absolute CD4þ T-cell count after
12–24 weeks of ARTwere paradoxically the most likely
to have detectable oral HPV DNA. Why the immune
benefit induced by ART in controlling other pathogens
does not generalize to HPV is unknown. Perhaps, damage
to HPV-specific Tor B cells occurs early in the course of
HIV disease and is irreversible, or ART-induced immune
reconstitution might preferentially expand the pool of
HPV-specific regulatory T cells, or reconstitution of
immune responses targeting other pathogens might
adversely affect HPV-specific immune reconstitution.
These findings underscore the importance of advancing
knowledge of immune system control of HPV and
determinants of HPV-specific immune deficits that are
associated with loss of that control in HIV-infected
people. Peripheral blood mononuclear cells and saliva
specimens were obtained and stored from time points
both before and after 24 weeks of ART in our study. The
next step will be to measure HPV-specific immune
responses in our cohort. Though we are not aware
of any T-cell functional assays that can reliably detect
HPV-specific responses in stored peripheral blood
mononuclear cells from HIV-infected patients (e.g.
cytokine production or T-cell proliferation), there are
ELISA assays that have been used in animal and human
vaccination studies to measure HPV genotype-specific
neutralizing antibody titers in mucosal secretions,
including saliva [23–25].One limitation of this study was incomplete follow-up.
Of the 500 study participants enrolled, evaluable oral
specimens for HPV DNA were not obtained from 6% of
study participants at week 16 and 13% at week 24.
However, we were able to obtain an evaluable oral
specimen at both of the pre-ART visits and both follow-
up time points in 388 (78%) study participants. Although
oral HPV infection can be chronic, the presence of HPV
DNA in the oral cavity may be intermittent [26]. Thus,
our collection of two throat wash specimens from before
ART initiation and two specimens during the period
12–24 weeks afterward improved the accuracy of the
results reported here, which was also demonstrated by the
poor concordance we observed between the two
specimens that were collected before ART as well as
the two collected during 12–24 weeks of follow-up.
All other large observational studies of oral HPV
have obtained only a single sample at baseline and at
follow-up intervals.
In conclusion, a causal link between HPV infection in the
oral cavity and oropharyngeal SCC, the higher prevalence
and incidence of oral HPV infection in men with HIV
than among men who are HIV-negative, and our
observation in an HIV-infected cohort of the failure of
ART to decrease oral HPV infection all lead us to be
concerned that oropharyngeal SCC may continue to
increase among those who are HIV-infected. Perhaps,
wide adoption of HPV vaccination for adolescent males
might ultimately reduce oropharyngeal SCC incidence,
even among those with concomitant HIV infection. In
the meantime, research studies that can define how HIV,
despite ART, permits unrestricted HPV infection in the
oral cavity are needed to provide the scientific under-
pinning for other preventive strategies.Acknowledgements
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